ESR1 and cancer: In adjusted models, csFCR was associated with having another cancer excluding non-melanoma skin (adjusted odds ratio [aOR], 2.64; 95% CI, 1.66-4.21), greater levels of stress (aOR, 2.40 per 1-SD increment; 95% CI, 1.98-2.91), having a prior recurrence (aOR, 2.26; 95% CI, 1.14-4.47), and having estrogen receptor-positive tumors (aOR, 1.60; 95% CI, 1.06-2.40).